Brief: Zentalis Pharmaceuticals On June 15 Entered Agreed to Terminate Its Collaboration With Zentera Therapeutics

Zentalis Pharmaceuticals

15/06/2023 11:48

June 15 (Reuters) - Zentalis Pharmaceuticals Inc
 ZNTL.O :
    * ZENTALIS PHARMACEUTICALS - ON JUNE 15, ENTERED INTO AN
AGREEMENT
TO TERMINATE ITS COLLABORATION AND LICENSE AGREEMENTS WITH
ZENTERA THERAPEUTICS
    * ZENTALIS PHARMACEUTICALS - DUE TO TERMINATION OF
AGREEMENTS,
REGAINED RIGHTS FROM ZENTERA FOR AZENOSERTIB, ZN-D5 AND ZN-C5 IN
GREATER CHINA
    * ZENTALIS PHARMACEUTICALS-DUE TO TERMINATION OF AGREEMENTS
NOW
HOLDS WORLDWIDE DEVELOPMENT & COMMERCIALIZATION RIGHTS TO
AZENOSERTIB, ZN-D5 AND ZN-C5
    * ZENTALIS PHARMACEUTICALS - IN ADDITION, ZENTALIS SOLD ITS
40.3%
EQUITY STAKE IN ZENTERA BACK TO ZENTERA FOR DE MINIMIS
CONSIDERATION

Source text for Eikon:  ID: 
Further company coverage:  ZNTL.O